U.S. Antitrust Investigation of Generics to Look into Two Dozen Drugs - Bloomberg
- Wall Street surges to new highs; transports set record
- lululemon athletica (LULU) Tops Q3 EPS by 4c; Adj.-Comps Outpaced Views
- Abbott (ABT) Files Complaint to Terminate Alere (ALR) Acquisition
- Costco Wholesale (COST) Tops Q1 EPS by 5c; Comps Up 1%, 2% Ex-Gas
- After-Hours Stock Movers 12/07: (VYGR) (LULU) (HRB( Higher; (OHRP) (VRNT) (CMTL) Lower (more...)
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
(Updated - November 3, 2016 2:23 PM EDT)
U.S. prosecutors are "bearing down" on generic pharma companies in a sweeping criminal investigation into suspected price collusion, according to Bloomberg. The antitrust investigation by the DOJ spans more than a dozen companies and two dozen drugs, sources told the news service. A grand jury probe is examining some executives and the first charges could emerge by the end of the year.
Companies mentioned in the report include Mylan (NASDAQ: MYL), Allergan (NYSE: AGN) and Teva Pharma (NYSE: TEVA), Lannett (NYSE: LCI), Impax Laboratories (NASDAQ: IPXL), Covis, Sun Pharma, Mayne, Endo (NASDAQ: ENDP), and Taro Pharma (NYSE: TARO).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mylan (MYL) Announces Restructuring Program; Sees Workforce Impact
- UPDATE: Linde to Resume Talks with Praxair (PX); Appoints Belloni as CEO
- Interpublic Group of Cos. (IPG) Says One of Standalone Agencies Contacted by DOJ - Bloomberg
Create E-mail Alert Related CategoriesCorporate News, ETFs, Hot Corp. News, Litigation, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!